SCHEMBL26641379

SCHEMBL26641379

CC(C)(C)OC(=O)N1CCC(F)(C#Cc2ccc(-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)cc2F)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 4/20 0.40
▸ CCNT1 O60563 1/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ CCNA1 P78396 1/20 0.40
▸ GPR119 Q8TDV5 6/20 0.39
▸ TACR1 P25103 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ ALOX5AP P20292 2/20 0.37
▸ FEN1 P39748 2/20 0.37
▸ TLR9 Q9NR96 2/20 0.37
▸ TLR7 Q9NYK1 2/20 0.37
▸ USP1 O94782 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ YAP1 P46937 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30643684 0.88 OPRD1 (0.42) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL26641508 0.86 OPRD1 (0.41) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL30830739 0.85 PARP1 (0.42) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL25940751 0.83 PARP1 (0.43) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL30136015 0.83 PARP1 (0.43) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL26642195 0.83 TLR9 (0.46) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL26641553 0.82 OPRD1 (0.42) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL29197031 0.81 PRMT5 (0.48) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL26641237 0.81 PRMT5 (0.39) PRMT5CCNT1CCNA2CDK2CDK9
SCHEMBL25035220 0.81 CYP11B2 (0.42) PRMT5CCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120092003-A CDK protein degrading agents, pharmaceutical compositions and therapeutic uses 拜欧斯瑞克斯公司 2025-06-03 — — CN disclosed
WO-2023220640-A1 CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-11-16 — — WO disclosed
Send feedback